By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Myriad Genetics slumped to a 52-week low earlier today, after the firm's stock was downgraded by investment bank JP Morgan.

Myriad fell to as low as $14.26 before rebounding slightly in the afternoon to $14.75 — still down 6 percent on the day.

JP Morgan downgraded Myriad's stock to "neutral" from "overweight" and cut its price target to $18 from $28.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.